They analyzed 44 blood specimens of 22 patients with NSCLC at baseline and within 4 weeks after PD-L1 blockade initiation, demonstrating that epigenetic signatures can reliably predict ICI prognosis. The gene discussed is CD274; the disease is non-small cell lung carcinoma.